Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 2, 2012, Pages 158-164

  Nagashima, Ayako ^a   Watanabe, Ryo ^a   Ogawa, Masahito ^b   Suzuki, Jun Ichi ^b   Masumura, Mayumi ^a   Hishikari, Keiichi ^a   Shimizu, Tomoko ^c   Takayama, Kiyoshi ^c   Hirata, Yasunobu ^b   Nagai, Ryozo ^b   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NB Health Laboratory   (Japan)

Author keywords

angiotensin II receptor blockers; myocardial ischemia; peroxisome proliferator activator receptor ; telmisartan

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMLODIPINE; GELATINASE A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM CHLORIDE; TELMISARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE SEPTUM; HEART VENTRICLE SIZE; HEART VENTRICLE WALL; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG PARTIAL AGONISM; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL INFARCTION; MYOCARDIUM; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; STROKE VOLUME; THIAZOLIDINEDIONES; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84865605064     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182592d7b     Document Type: Article

References (19)

1. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension. 2004;43:993-1002.
2. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med hypotheses. 2005;64:476-478.
3. Sugimoto K, Qi NR, Kazdova L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006;47:1003-1009.
4. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054-2057.
5. Kobayashi N, Ohno T, Yoshida K, et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens. 2008;21:576-581.
6. Yamagishi S, Matsui T, Nakamura K, et al. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation. Protein Pept Lett. 2008; 15:850-853.
7. Sugimoto K, Kazdova L, Qi NR, et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens. 2008;26:1209-1215.
8. Hao GH, Niu XL, Gao DF, et al. Agonists at PPAR-gamma suppress angiotensin ii-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol. 2008;153:1409-1419.
9. Goyal S, Arora S, Bhatt TK, et al. Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes. Chem Biol Interact. 2010;185:271-280.
10. Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator- activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke. 2010;41:1798-1806.
11. Shimada T, Yoshiyama M, Takeuchi K, et al. Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Cardiovasc Res. 1998;37:618-626.
12. Liang B, Leenen FH. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. J Cardiovasc Pharmacol. 2008;51:457-466.
13. Olivetti G, Capasso JM, Meggs LG, et al. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res. 1991;68:856-869.
14. Anversa P, Olivetti G, Capasso JM. Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol. 1991;68:7D-16D.
15. Clauser E. Molecular structure and function of angiotensin ii receptors. Nephrologie. 1998;19:403-410.
16. Taylor K, Patten RD, Smith JJ, et al. Divergent effects of angiotensinconverting enzyme inhibition and angiotensin ii-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol. 1998;31:654-660.
17. Matsumura S, Iwanaga S, Mochizuki S, et al. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115:599-609.
18. Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase- 2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1847-H1860.
19. Vanhoutte D, Schellings M, Pinto Y, et al. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69:604-613.